UK Launches AI Research Screening Platform to Boost MedTech Sector
The UK government is boosting its MedTech sector with a new digital platform. The AI Research Screening Platform (AIR-SP), developed by Gemini AI, aims to make the UK more appealing to investors and solidify its global healthcare leadership. This initiative is part of the government's Plan for Change, transforming the NHS from analogue to digital.
AIR-SP will debut in a significant trial involving nearly 700,000 women. The platform will support a landmark NIHR-funded study, assessing AI tools for breast cancer detection. This marks the first major use of AIR-SP, demonstrating its potential to accelerate diagnosis and improve patient outcomes.
Currently, AI trials in the NHS face delays due to fragmented IT infrastructure. AIR-SP addresses this by creating a single cloud platform connected to all NHS trusts. This will enable multiple trusts to participate simultaneously in large-scale AI trials, trialling multiple AI tools in one shared environment.
Backed by nearly 6 million GBP in government funding, AIR-SP is expected to be rolled out for research use by 2027. This platform represents a significant shift in how AI trials are conducted within the NHS, driving investment, economic growth, and ultimately, better patient care.
Read also:
- MRI Scans in Epilepsy Diagnosis: Function and Revealed Findings
- Hematology specialist and anemia treatment: The role of a hematologist in managing anemia conditions
- Bluetongue Outbreaks Confirmed in Wales: APHA Urges Farmers to Act
- Exploring the Essentials: Understanding Magnetism at its Core in an Educational Perspective
